Peptides for women
Peptides for women in midlife - what people use them for, where evidence is limited, and how a clinician evaluates whether an option may be appropriate.
Start here
More in Peptides for women
- Tesamorelin for Menopause Belly Fat: Does It Work?Tesamorelin should not be marketed as a menopause belly-fat shortcut. It is a prescription growth hormone-releasing factor analog with evidence in HIV-associated lipodystrophy, not menopause weight gain. In one randomized placebo-controlled trial in HIV-infected patients with central fat accumulation, tesamorelin reduced visceral fat by about 18%. DailyMed labeling is tied to reduction of excess abdominal fat in adults with HIV and lipodystrophy, with pregnancy and other safety limits. A safer discussion treats tesamorelin as an evidence-transfer warning, not an established menopause treatment. [1]
- TB-500 After Menopause: Evidence, Safety, and FDA StatusTB-500 should not be promoted as a recovery or repair peptide for women after menopause. TB-500 is commonly discussed as a thymosin beta-4 fragment, but much of the wound-healing evidence is preclinical or early-stage and not a menopause outcome program. FDA lists thymosin beta-4 fragment LKKTETQ among bulk drug substances that may present significant safety risks in compounding. Clinician-led care should treat TB-500 as a safety-limit topic, especially for injectable or stacked peptide use. [4]
- Sermorelin for Women After Menopause: Evidence and SafetySermorelin after menopause should be treated as a growth hormone-axis evidence question, not as an established menopause treatment. Geref, a sermorelin acetate product, had FDA-approved history for pediatric growth-hormone deficiency and diagnostic use, but it was discontinued in 2008 and is not the same as a current compounded anti-aging product. [2] [3] In the most relevant older-adult growth hormone-releasing hormone analog study, 19 adults aged 55 to 71 had growth hormone/insulin-like growth factor 1 activation and increased skin thickness after 16 weeks, but weight and sleep did not improve, and lean-mass, insulin-sensitivity, well-being, and libido signals favored men rather than women. [1]
- CJC-1295 and Ipamorelin After Menopause: Do They Work?CJC-1295 and ipamorelin should not be treated as established menopause therapies. CJC-1295 increased growth hormone 2- to 10-fold for at least 6 days and insulin-like growth factor 1 1.5- to 3-fold for 9 to 11 days in healthy adults, but that was biomarker evidence, not a trial of women after menopause. Ipamorelin human data also show growth-hormone stimulation, while a 117-patient postoperative-ileus trial did not show significant efficacy differences on key outcomes. FDA safety materials also flag CJC-1295 and ipamorelin-related compounding concerns. [1]
- PT-141 After Menopause: Does It Help Libido?Bremelanotide, often discussed online as PT-141, should not be sold as a menopause libido peptide. DailyMed labeling says VYLEESI is indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The pivotal RECONNECT trials also studied premenopausal women, not postmenopausal women. In practice, bremelanotide belongs in an evidence-limit article: it may be relevant to sexual-medicine education, but a clinician should not treat premenopausal hypoactive sexual desire disorder data as evidence for desire problems after menopause. [1]
- BPC-157 After Menopause: Evidence, FDA Status, and SafetyBPC-157 is not an established menopause treatment. A 2025 review found only three human pilot reports, none testing menopause symptoms. [1] FDA identifies compounding uncertainties involving immunogenicity, peptide impurities, and active-ingredient characterization. [6] On July 23, 2026, an advisory committee voted 8-6, with 1 abstention, to recommend adding BPC-157 to the 503A compounding list, contrary to FDA staff's recommendation. The vote is nonbinding: it did not itself change list status or approve a finished BPC-157 drug. [7] [8] [9]
- AOD-9604 for Menopause Weight Loss: Does It Work?AOD-9604 should not be framed as a glucagon-like peptide-1 alternative for menopause weight loss. It is a synthetic fragment related to human growth hormone, not an FDA-approved obesity medication. FDA has listed AOD-9604 among bulk drug substances that may present significant safety risks in compounding and has identified serious adverse events that may be associated with it, while noting causality is unclear. Clinician-led care should treat AOD-9604 as an evidence and safety limits topic, not an established midlife weight-loss treatment. [1]
Common questions
Did tesamorelin reduce visceral fat in trials?
Yes, but in HIV-associated lipodystrophy. A randomized placebo-controlled trial reported about an 18% reduction in visceral fat in HIV-infected patients with central fat accumulation.
Is TB-500 established for recovery after menopause?
No. Recovery claims for TB-500 are ahead of direct human evidence in women after menopause. Most claims borrow from thymosin beta-4 biology, animal work, or non-menopause contexts.
Is sermorelin FDA-approved for menopause or anti-aging?
No. FDA records show Geref, a sermorelin acetate product, was approved in 1997 for pediatric growth-hormone deficiency history and related diagnostic use, then discontinued in 2008. That history does not approve compounded sermorelin for menopause, weight loss, energy, or anti-aging.
Are peptides safe for women after menopause?
Safety depends on the exact peptide, dose, route, source, and health history. FDA materials flag multiple compounded peptide substances, while approved labels have specific warnings. A safe review should name the product and include at least 1 clear monitoring plan.
What did CJC-1295 human studies show?
In healthy adults aged 21 to 61, one CJC-1295 injection increased mean growth hormone 2- to 10-fold for at least 6 days and insulin-like growth factor 1 1.5- to 3-fold for 9 to 11 days. That is biomarker evidence, not menopause outcome evidence.
Is bremelanotide the same topic as PT-141?
PT-141 is a common name used for bremelanotide. The prescription product VYLEESI contains bremelanotide and is FDA approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.
Is BPC-157 established for menopause symptoms?
No. Current BPC-157 evidence does not establish benefit for hot flashes, weight, libido, skin aging, joint pain, gut symptoms, or recovery after menopause. A 2025 review found only 3 human pilot reports.
Is AOD-9604 FDA approved for weight loss?
No. AOD-9604 is not an FDA-approved obesity drug. Do not compare it with semaglutide or tirzepatide as though they are equivalent treatment options.